BioCentury | Nov 18, 2019

The transcription factors ID1 and ID3 as targets for AMD and retinopathy

...in the AMD mouse model. AngioGenex Inc. has Idantirx in preclinical testing for cancer. TARGET/MARKER/PATHWAY: Inhibitor of DNA binding...
...Benezra, Memorial Sloan Kettering Cancer Center, New York, N.Y. email: benezrar@mskcc.org Claire Quang Memorial Sloan Kettering Cancer Center Inhibitor of DNA binding...
BioCentury | Aug 23, 2018
Distillery Techniques

Biomarkers

...between cardiac atrial and atrioventricular conduction, which are disrupted in atrial fibrillation, and SNPs on inhibitor of DNA binding...
...University of Washington, Seattle, Wash. email: nsotoo@u.washington.edu Jennie Walters University Medical Center Utrecht University of Washington Forkhead box P1 (FOXP1) Inhibitor of DNA binding...
BioCentury | May 30, 2018
Distillery Therapeutics

Cancer

...in models of metastatic colorectal cancer. TARGET/MARKER/PATHWAY: Transforming growth factor β receptor II (TGFβ-RII; TGFBR2); inhibitor of DNA binding...
...10, 2018 doi:10.1158/0008-5472.CAN-17-3003 CONTACT: Elisabeth Letellier, University of Luxembourg, Belvaux, Luxembourg email: elisabeth.letellier@uni.lu Sandi Wong University of Luxembourg Inhibitor of DNA binding...
BioCentury | Nov 2, 2016
Distillery Therapeutics

Cancer

...Next steps including testing ID2-expressing DCs in animal models of breast and other cancers. TARGET/MARKER/PATHWAY: Inhibitor of DNA binding...
BioCentury | Nov 1, 2016
Distillery Therapeutics

Cancer

...other animal models of melanoma. TARGET/MARKER/PATHWAY: Peroxisome proliferation activated receptor γ coactivator 1-α (PGC-1α; PPARGC1A); inhibitor of DNA binding...
BioCentury | Oct 27, 2016
Targets & Mechanisms

T cell gas, tumor brake

...University of Pittsburgh, Pittsburgh, Pa. Targets and Compounds AMPK - AMP-activated protein kinase ID2 - Inhibitor of DNA binding...
...without driving tumor metabolism, which can occur when tumor cells highly express PGC-1α. ID2 - Inhibitor of DNA binding...
BioCentury | May 14, 2015
Distillery Therapeutics

Therapeutics: Inhibitor of DNA binding 1 (ID1)

...Inc. has AGX-51 , an inhibitor of ID1, in preclinical testing to treat cancer. TARGET/MARKER/PATHWAY: Inhibitor of DNA binding...
BioCentury | May 14, 2015
Translation in Brief

Check Your ID

...joint study by Regeneron Pharmaceuticals Inc. and researchers at Weill Cornell Medical College that positions inhibitor of DNA binding...
BioCentury | May 15, 2014
Distillery Therapeutics

Indication: Cancer

...Cancer Brain cancer Activin receptor-like kinase 2 (ALK2; ACVR1); SMAD family member 1 (MADH1; SMAD1); inhibitor of DNA binding...
BioCentury | Mar 3, 2014
Clinical News

AngioGenex preclinical data

...Association of Cancer Research meeting in Washington, D.C. AGX-51 is a small molecule that inhibits inhibitor of DNA binding...
Items per page:
1 - 10 of 18